US 11,873,339 B2
Anti-C10orf54 antibodies and uses thereof
John Lippincott, Burlingame, CA (US); Edward Thein Htun Van Der Horst, Burlingame, CA (US); Sung Young Kim, Burlingame, CA (US); Leonard G Presta, Burlingame, CA (US); and Jan-Willem Theunissen, Burlingame, CA (US)
Assigned to PIERRE FABRE MEDICAMENT, Boulogne-Billancourt (FR)
Filed by PIERRE FABRE MEDICAMENT, Boulogne-Billancourt (FR)
Filed on Jun. 22, 2020, as Appl. No. 16/908,347.
Application 16/908,347 is a continuation of application No. 15/534,982, granted, now 10,766,959, previously published as PCT/US2015/065331, filed on Dec. 11, 2015.
Claims priority of provisional application 62/090,880, filed on Dec. 11, 2014.
Prior Publication US 2020/0385473 A1, Dec. 10, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); A61K 31/4025 (2006.01); A61K 31/404 (2006.01); A61K 31/5517 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2827 (2013.01) [A61K 31/404 (2013.01); A61K 31/4025 (2013.01); A61K 31/5517 (2013.01); A61K 39/39558 (2013.01); A61K 47/6803 (2017.08); A61K 47/6851 (2017.08); A61K 47/6873 (2017.08); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/73 (2013.01); C07K 2317/74 (2013.01); C07K 2317/92 (2013.01)] 24 Claims
 
1. An isolated antibody, or antigen-binding fragment thereof, that binds to a first group of C10orf54 proteins or chimeric proteins designated CC1 (SEQ ID NO: 1079), CC4 (SEQ ID NO: 1245), CC5 (SEQ ID NO: 1246), CC8 (SEQ ID NO: 1249), and CC10 (SEQ ID NO: 1251), and does not bind to a second group of C10orf54 proteins or chimeric proteins designated CC2 (SEQ ID NO: 1243), CC3 (SEQ ID NO: 1244), CC6 (SEQ ID NO: 1247), CC7 (SEQ ID NO: 1248), and CC9 (SEQ ID NO: 1250);
wherein the antibody is the antibody 230A, comprising:
a heavy chain variable domain comprising the following three CDRs, respectively CDR-H1 having the sequence SEQ ID NO: 1302, CDR-H2 having the sequence SEQ ID NO: 1365 and CDR-H3 having the sequence SEQ ID NO: 1402, and a light chain variable domain comprising the following three CDRs, respectively CDR-L1 having the sequence SEQ ID NO: 1455, CDR-L2 having the sequence SEQ ID NO: 1103 and CDR-L3 having the sequence SEQ ID NO: 1505.